The objective of this study was to identify molecular alterations associated with disease outcomes for white and black patients with endometrioid endometrial cancer (EEC). METHODS: EEC samples from black (n 5 17) and white patients (n 5 13) were analyzed by proteomics (liquid chromatography-tandem mass spectrometry) and transcriptomics (RNA-seq). Coordinate alterations were validated with RNA-seq data from black (n 5 49) and white patients (n 5 216). Concordantly altered candidates were further tested for associations with race-specific progression-free survival (PFS) in black (n 5 64) or white patients (n 5 267) via univariate and multivariate Cox regression modeling and log-rank testing. RESULTS: Discovery analyses revealed significantly altered candidate proteins and transcripts between black and white patients, suggesting modulation of tumor cell viability in black patients and cell death signaling in black and white patients. Eighty-nine candidates were validated as altered between these patient cohorts, and a subset significantly correlated with differential PFS. White-specific PFS candidates included serpin family A member 4 (SER-PINA4; hazard ratio [HR], 0.89; Wald P value 5 .02), integrin subunit a3 (ITGA3; HR, 0.76; P 5 .03), and Bet1 Golgi vesicular membrane trafficking protein like (BET1L; HR, 0.48; P 5 .04). Black-specific PFS candidates included family with sequence similarity 228 member B (FAM228B; HR, 0.13; P 5 .001) and HEAT repeat containing 6 (HEATR6; HR, 4.94; P 5 .047). Several candidates were also associated with overall survival (SERPINA4 and ITGA3) as well as PFS independent of disease stage, grade and myometrial invasion (SERPINA4, BET1L and FAM228B). CONCLUSIONS: This study has identified and validated molecular alterations in tumors from black and white EEC patients, including candidates significantly associated with altered disease outcomes within these patient cohorts.
INTRODUCTION
Endometrial cancer is now the second most prevalent cancer among women in the United States. 1 Historically, white women have been more likely to be diagnosed with endometrial cancer, but black women have been more than twice as likely to die of this disease. [2] [3] [4] Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program show that the incidence of endometrial cancer is decreasing in white women and increasing in other races to the point where the incidence is almost equal between black and white women. Mortality, however, is still almost double in black women versus white women. 2 The causes of this disparity are multifactorial and include socioeconomic, cultural, and biological factors. 5 Although population studies associate issues related to access to care and differential treatment with poor outcomes in blacks versus whites with endometrial cancer, 3 racial disparities remain in health care settings in which patients receive equal care. 6 In an analysis of data from the Gynecologic Oncology Group, investigators demonstrated 20% worse survival among 169 blacks versus 982 whites receiving treatment for advanced endometrial cancer in clinical trials in which participants received uniform care, regardless of race or socioeconomic status. 7 The disparity remained when they controlled for stage, histology, body mass index, and comorbidities. 7 Further investigation demonstrated that blacks were less responsive to chemotherapy regimens consistently across several clinical studies, and this suggested a potential biological component to the observed racial disparity. Several studies have focused on identifying molecular alterations in endometrial cancer that differ between blacks and whites, but further associations of these candidates with outcomes have not been independently validated. Prior studies have demonstrated that tumors with p53 mutations, 8 wild-type phosphatase and tensin homolog (PTEN), 9 and human epidermal growth factor receptor 2 (Her-2) 10 are more common in blacks than whites with endometrial cancer, and this suggests that these alterations may in part explain the racial disparity in outcomes. Thus far, discovery-based investigations have not validated prognostic race-associated molecular alterations. 11, 12 Further investigations are warranted because the mortality of aggressive subtypes of endometrial cancer is growing faster for blacks than other racial groups. 13 In the current study, we conducted an integrated proteomic and transcriptomic analysis of black and white endometrioid endometrial cancer (EEC) to identify and validate molecular alterations associated with patient outcomes for an expanded cohort of EEC patients 14 with the hope that this investigation would provide further insights into the biological differences underlying the disease biology of EEC within these patient cohorts.
MATERIALS AND METHODS

Tissue Samples for Whole-Transcriptome Sequencing and Mass Spectrometry-Based Proteomics
Fresh-frozen cancer specimens from EEC patients were collected under institutional review board-approved protocols. Patient race was determined from a review of patient data derived from clinical or pathology charts. Tissue specimens were hematoxylin-eosin-stained and evaluated by a board-certified gynecologic pathologist to confirm the diagnosis and to qualify specimens for inclusion in the study. Thin (10-lm) tissue sections were cut with a cryostat and placed on polyethylene naphthalate membrane slides. After staining with aqueous hematoxylin-eosin, laser capture microdissection was used to harvest tumor cells from thin sections (mean tumor cell area captured, 30 6 7 mm 2 ). Samples for total RNA extraction were collected in 100 lL of 13 RLT buffer (Qiagen), and samples for proteomic analyses were collected in 100 lL of high-performance liquid chromatography-grade water.
Whole-Transcriptome Sequencing
Total RNA was isolated, enriched for poly(A) RNA, and subjected to library preparation and barcoding for nextgeneration whole-transcriptome sequencing on a SOLiD 5500xl series genetic analyzer (Thermo Fisher Scientific, Waltham, Massachusetts). Transcriptome discovery data were filtered so that abundance levels of candidates satisfied the threshold of 1 for reads per kilobase of transcript per million mapped reads (RPKM) in at least twothirds of the patient samples analyzed for a given comparator cohort. Significantly altered transcripts between black and white patients in discovery RNA-seq were determined with a Wilcoxon rank-sum test on the basis of RPKM values. A Wilcoxon P value < .05 was considered to indicate a significant difference (see the online supporting information for further details).
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Proteomics
Tissue samples were processed and subjected to LC-MS/ MS-based proteomic analyses as previously described. 15 Proteomic discovery data were filtered so that abundance levels of candidates satisfied a peptide spectral match 2 in at least two-thirds of the patients analyzed for a given comparator cohort. Significantly altered proteins between black and white patients in discovery LC-MS/MS analyses were identified with a Wilcoxon rank-sum test on the basis of peptide spectral matches normalized to the patient sample exhibiting the lowest total peptide spectral match counts. A Wilcoxon P value < .05 was considered to indicate a significant difference (see the online supporting information for further details).
Biostatistical Analyses
All protein (UniProt Accessions) and transcript identifiers (Gene Symbol/National Center for Biotechnology Information Gene ID) were mapped with Ingenuity Pathway Analysis (Qiagen, Redwood City, California) to enable direct comparisons of candidate data across analytical platforms. The significance and abundance trends of concordant protein and transcript candidates from discovery efforts were validated with normalized RNA-seq V2 data from The Cancer Genome Atlas (TCGA) 14 across two-thirds of a given comparator cohort; Wilcoxon P < .05; validation TCGA cohort). The validation TCGA cohort comprised patients with primary tumors only. Furthermore, because our discovery cohort included tissue samples collected from the Gynecologic Oncology Group and Duke University, samples originating from these sites were removed from the validation TCGA cohort. Functional pathway analyses were performed with Ingenuity Pathway Analysis with the core-analysis function and default settings. 17 Univariate and multivariate Cox regression analyses and Kaplan-Meier analyses with log-rank testing of progression-free survival (PFS) and overall survival were performed for all available black and white EEC patients in TCGA with the survival package (version 2.37-7) in R (version 3.1.2). For Kaplan-Meier curves, high transcript expression versus low transcript expression was defined by the median cut point. Survival and clinical data were extracted from the cgdsr package (version 1.2.5) in R on August 18, 2016. PFS and overall survival were capped at 60 months, and log 2 -transformed normalized gene expression data were used for survival analysis. The patient's disease stage, grade, and myometrial invasion were categorized into 2 levels (low and high) for the adjusted survival analysis.
RESULTS
Proteomic and Transcriptomic Analyses of EEC Tumor Tissues Identify Conserved Molecular Alterations Between Black and White Patients With EEC
Proteomic and transcriptomic analyses were performed on pathologically defined, fresh-frozen tumor cell populations from EEC patient tissues obtained from black (n 5 17) and white EEC patients (n 5 13; discovery cohort in Table 1 ). Prefiltering of the transcriptomic and proteomic results (see the online supporting information) resulted in 12,942 transcripts and 966 proteins for significance testing, which identified 612 transcripts (275 elevated and 337 decreased in black patients) and 94 proteins (32 elevated and 62 decreased in black patients) altered between black and white patients (Wilcoxon P < .05). Ten of these candidates were concordantly altered at the protein and transcripts levels ( Fig. 1 and Supporting Tables 1 and 2 [see online supporting information]). These 10 candidates were elevated in white patients and encoded predominantly cytoplasmic and membrane-localized protein variants of diverse functions ( Table 2 ).
The correlation of the 612 altered transcripts with global proteomic data revealed 25 transcripts that were not altered in proteomic data ("transcript 6 ¼ protein" in Fig. 1 ), and they were removed from consideration in downstream validation. The remaining 587 altered transcripts were then compared with public RNA-seq data from an independent cohort of black (n 5 49) and white patients with EEC (n 5 216; validation TCGA cohort in Table 1 ). Eighty-nine of these candidates exhibited concordant alterations within the validation cohort ( Fig. 1 and Supporting Table 3 [see online supporting information]). Three of the 89 candidates-eukaryotic translation elongation factor 2 (EEF2), junction plakoglobin (JUP), and unconventional myosin IC (MYO1C)-were altered at both the protein and transcript levels within discovery analyses (these candidates are labeled with a superscripted a in Table 2 and with an asterisk in Supporting Table 3 ). In addition, significantly altered proteins that were identified by LC-MS/MS analyses were correlated with reversephase protein array data for white (n 5 220) and black ) in black patients versus white patients. The validated candidates (89 transcripts) were combined with the 94 altered proteins identified in proteomic analyses and subjected to molecular pathway analyses to identify the predicted functional regulatory roles of these molecular alterations in the context of disease pathology in white and black patients (Table 3 and  Supporting Tables 4 and 5 [see online supporting information]). These analyses revealed that candidates which were significantly increased in black patients correlated with predicted activation of tumor cell viability and nucleic acid metabolism as well as inhibition of cell death signaling. Candidates that were significantly decreased in black patients correlated with the activation of molecular signaling pathways regulating viral infection but with the inhibition of those regulating cell death and necrosis. To determine whether molecular alterations identified between black and white EEC patients correlated with differential disease outcomes, the 89 validated transcript candidates that were altered between black and white patients were further analyzed for their association with PFS within white (n 5 267) and black TCGA patients (n 5 64) by univariate and multivariate Cox regression modeling ( Fig. 2 and Supporting Tables 6-8 [see online supporting information]). These analyses identified both discrete and overlapping candidates differentially expressed between black and white patients that were further Proteomic and transcriptomic analyses reveal conserved molecular alterations between black and white endometrioid endometrial cancer patient tissues. Significantly altered transcripts and proteins (Wilcoxon P < .05) were filtered to remove transcripts that were identified but were not significantly altered in proteomic analyses (transcript 6 ¼ protein). Validated transcript alterations (The Cancer Genome Atlas) and altered protein candidates were combined and subjected to molecular pathway analyses. Candidates highlighted in red failed, whereas those in green passed a given filter step. RNAseq indicates RNA sequencing.
significantly (Wald P .05) associated with differential PFS. Twelve transcripts were significantly correlated with PFS in white patients (Table 4 and Supporting Table 6 ), and 8 of these remained significant after adjustments for disease stage, grade, and myometrial invasion. Five of these candidates were also significantly associated with overall survival (Supporting Table 9 [see online supporting information]) and exhibited concordant trends for disease outcome as PFS candidates. All transcript candidates associated with a low risk of progression (hazard Candidates altered between black and white EEC patients are associated with altered disease outcomes for black or white EEC patient cohorts. Validated alterations were assessed for their association with differential PFS by univariate Cox modeling in race-specific patient cohorts (Wald P < .05). PFS-associated candidates were further assessed with multivariate analyses and for associations with overall patient survival. The distributions of PFS-associated candidates are defined in the 2-way Venn diagram. The number of significantly altered candidates considered (Wilcoxon P < .05) and passing multivariate analyses or associations with overall survival (Wald P < .05) are highlighted in green. EEC indicates endometrioid endometrial cancer; PFS, progression-free survival.
ratio [HR]
, <1) were elevated in white patients, and the majority of the candidates associated with a high risk of progression (HR, >1) were decreased in white patients (Table 4) . In black patients, 11 transcript candidates were significantly associated with PFS (Table 4 and Supporting  Table 7 ), and 3 of these remained significant after adjustments for disease stage, grade, and myometrial invasion. None of these were co-associated with overall survival. Two of these transcript candidates, DSN1 homolog MIS12 kinetochore complex component (DSN1) and DNA ligase 3 (LIG3), were also associated with PFS in white EEC patients. DSN1 correlated with a high risk of disease progression in both white and black patient cohorts, whereas LIG3 correlated with a low risk of disease progression in white patients but a high risk of disease progression in black patients (Table 4 ). All transcript candidates associated with a low risk of disease progression in black patients were decreased in black patients, whereas candidates elevated in black patients correlated with both low and high risks of disease progression (Table 4) . Further analyses of race-specific candidates associated with PFS by log-rank testing of categorized survival trends revealed a subset that remained significantly associated with PFS (Fig. 3) . This subset included serpin family A member 4 (SERPINA4; also by overall survival; HR for white patients, 0.83; Wald P 5 .0014; log-rank Abbreviations: ABCA5, ATP binding cassette subfamily A member 5; AP4S1, adaptor-related protein complex 4 r1 subunit; BET1L, Bet1 Golgi vesicular membrane trafficking protein like; CAPN6, calpain 6; CI, confidence interval; C19orf25, chromosome 19 open reading frame 25; DAP, death-associated protein; DSN1, DSN1 homolog MIS12 kinetochore complex component; EPM2A, EPM2A laforin glucan phosphatase; FAM228B, family with sequence similarity 228 member B; HEATR6, HEAT repeat containing 6; HR, hazard ratio; ITGA3, integrin subunit a3; LIG3, DNA ligase 3; MALL, Mal T-cell differentiation protein like; PBX1, PBX homeobox 1; PNPT1, polyribonucleotide nucleotidyltransferase 1; PSMD5-AS1, PSMD5 antisense RNA 1 (head to head); SERPINA4, serpin family A member 4; SLC24A1, solute carrier family 24 member 1; UCP2, uncoupling protein 2; WDR97, WD repeat domain 97; WTAP, Wilms tumor 1 associated protein.
Significantly altered (Wilcoxon P < 0.05) progression-free survival-associated candidates were identified with univariate Cox modeling (Wald P < 0.05). a Candidates significantly associated with progression-free survival in black and white patients. b Candidates significantly associated with differential overall survival. c Candidates with significant multivariate Cox analyses (Wald P < .05) for stage, grade, and myometrial invasion.
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October 15, 2017 P 5 .0031), integrin subunit a3 (ITGA3), and Bet1 Golgi vesicular membrane trafficking protein like (BET1L) from white-only PFS candidates and family with sequence similarity 228 member B (FAM228B) and HEAT repeat containing 6 (HEATR6) from black-only PFS candidates (Fig. 3) . We further analyzed the association of this candidate subset with PFS within the combined black and white cohorts and found that SERPINA4 (HR, 0.89; P 5 .007) and ITGA3 (HR, 0.76; P 5 .02) remained significantly associated with PFS within these combined cohorts, representing candidates with independent prognostic value.
DISCUSSION
The goals of this study were to investigate and validate molecular alterations between highly enriched tumor cell populations harvested from black and white patients' EEC tumors and to further consider these candidates with respect to race-specific disease outcome events. We identified conserved molecular alterations in black and white patients' EEC tumors that correlated with functional roles supporting the impairment of cell death signaling in both black and white patients and the impairment of viral infection signaling but increased cell viability and nucleic acid metabolism signaling in black patients. We further identified candidates that were co-altered in black and white patients at both the protein and transcript levels, several of which have been proposed as biomarkers for diverse disease pathologies, including elevations of JUP as a marker of atherosclerosis 18 and PDZ and LIM domain 5 (PDLIM5) as a marker of mammary tumor formation. 19 Our analyses further demonstrated multiple transcript alterations between black and white patients significantly associated with PFS in these patient groups. Several PFS candidates remained significantly associated with altered PFS after log-rank testing and multivariate modeling adjusted for patient disease stage, grade, or myometrial invasion. Genes remaining associated with PFS after multivariate correction in white patients included SER-PINA4 and BET1L, whereas those in black patients included FAM228B. SERPINA4, a white-specific PFS candidate correlating with better PFS, is a serine protease inhibitor that has been shown to inhibit angiogenesis as well as tumor growth in diverse cancer types. 20, 21 A loss of SERPINA4 expression has been shown to correlate with poor outcomes for patients with colorectal cancer as well as hepatocellular cancer. 21, 22 BET1L, a white-specific PFS candidate associated with a decreased risk for experiencing poor PFS, is a vesicle-soluble, N-ethylmaleimidesensitive factor protein receptor regulating vesicular transport within the Golgi apparatus. 23 Notably, recent Figure 3 . Kaplan-Meier plots of significantly altered candidates between black and white EEC patients associated with differential progression-free survival in white or black EEC patient cohorts. Candidates with log-rank P values < .05, denoted with a green or red square, were decreased or elevated in black patients, respectively. *These candidates had significant multivariate Cox analyses (Wald P < .05) for disease stage, grade, and myometrial invasion. #These candidates were also significantly associated with differential overall survival. BET1L indicates Bet1 Golgi vesicular membrane trafficking protein like; EDC, endometrioid endometrial cancer; FAM228B, family with sequence similarity 228 member B; HEATR6, HEAT repeat containing 6; ITGA3, integrin subunit a3; SERPINA4, serpin family A member 4.
genome-wide association studies investigating variants associated with the formation of uterine fibroids identified a single-nucleotide polymorphism in the 3 0 -untranslated region of the BET1L gene directly associated with a decreased risk for developing uterine fibroids in women of European American descent. 24, 25 FAM228B, a black-specific PFS candidate associated with better PFS, is a theoretical protein-coding gene encoded on chromosome 2p23.3 that is otherwise largely of unknown function. Furthermore, LIG3, observed as being associated with poor PFS for black patients but improved PFS for white patients, regulates a highly error-prone subtype of alternative nonhomologous end joining DNA repair, termed microhomology-mediated end joining, that can result in an elevated risk of genome instability and increased cancer risk. 26 It is, therefore, possible that LIG3-associated microhomology-mediated end joining signaling may have a greater mechanistic role in endometrial cancer tumor cell biology in black patients versus white patients, and this results in the observed dichotomous relation between LIG3 and the differential risk of progression between these patient cohorts. The significance of this finding will be clarified in subsequent validation efforts, which are the subject of ongoing studies.
Our analysis has identified overarching trends in outcome-associated molecular alterations in black and white EEC patients. To clarify the race-specific role of these candidates as well as the concept of race-specific biology underlying EEC disease progression, further molecular characterization of expanded racially diverse patient populations is necessary and will be the focus of subsequent validation efforts. Nonetheless, our findings underscore that alterations in patient outcomes may be due to significant differences in molecular tumor biology influencing disease progression in race-specific ways. Recent efforts to study associations between genetic definitions of race and disease outcome in endometrial cancer patients have provided evidence to support the importance of this line of investigation in understanding the molecular disease biology across diverse racial backgrounds. 27 Rocconi et al 27 reported that the level of measurable ancestry-informative genetic markers indicative of an African genotype directly correlated with poor PFS in endometrial cancer patients. This study further revealed that 35% of self-described black patients exhibited American Indian or European genotypes, whereas 23% of self-described white patients were of American Indian or African ancestry with similar measures. This evidence brings to light that the significance of the findings we report herein may be affected by the racial admixture of the EEC patients analyzed with respect to measures of ancestry-informative genetic markers. These findings further argue that additional investigations of race-specific molecular alterations are necessary to clarify the molecular foundations of racial disparities in endometrial cancer disease biology and the ways in which they may affect patient outcomes. It could be envisioned that race-specific molecular alterations directly associated with differential disease outcomes could be leveraged to improve the identification and diagnosis of EEC patients.
Our findings of molecular alterations between white and black EEC patients and their association with altered patient outcomes add further insight into the molecular basis of endometrial cancer racial disparities. These alterations warrant further investigation for their mechanistic role in the molecular disease pathologies underlying EEC in both white and black patients.
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